Loading...
Loading...
Contributors:
Dataset URI:
10.6084/m9.figshare.34747739.v1DNA methylation alterations are stable, biologically informative, and detectable in tissue and circulating DNA, making them promising biomarkers for non-small cell lung cancer (NSCLC). However, few methylation biomarkers have entered routine clinical practice. We aimed to characterize the evolution and translational challenges of this field. Publications on NSCLC, DNA methylation, and biomarker applications were retrieved from the Web of Science Core Collection through 31 December 2025. After PRISMA-based screening, bibliometric and knowledge-map analyses were performed. A total of 1,910 publications were included. Annual output increased after 2010 and peaked in 2022. Lung Cancer was the most productive journal, whereas Cancer Research had the highest citation impact. China contributed the largest publication volume, while the United States had the highest citation impact. Foundational studies focused on promoter hypermethylation, methylation-specific PCR, and methylated DNA detection in accessible biospecimens. Research priorities shifted from candidate-gene studies toward methylation signatures, liquid biopsy, multi-omics integration, immunotherapy-related applications, and computational modeling. NSCLC methylation biomarker research has evolved toward integrated translational frameworks. Future progress requires multicenter validation, standardized platforms, clinically defined methylation panels, and AI-assisted integration. www.crd.york.ac.uk/prospero identifier is CRD420261426546. DNA methylation is a chemical modification of DNA that can influence how genes function without changing the DNA sequence. These changes can be detected in lung tumor tissue, blood, and other body fluids and may help diagnose or monitor non-small cell lung cancer. However, few DNA methylation tests are currently used in routine clinical practice. We analyzed 1,910 publications from 1999 to 2025 to examine how this research field has developed and why clinical translation remains limited. Research has shifted from individual methylated genes and tissue-based tests toward multigene panels, liquid biopsy, multi-omics analysis, and computer-assisted prediction. An additional assessment of representative clinical studies found promising diagnostic and prognostic results, but testing methods, sample types, cutoff values, and validation strategies varied substantially. Many studies also lacked independent validation or direct comparison with established clinical tests. Standardized testing platforms, clearly defined clinical uses, and multicenter prospective validation will be needed before DNA methylation biomarkers can be widely adopted in clinical care.
Keyword(s):
bibliometric analysis; Biological Sciences not elsewhere classified; biomarker; Biophysics; Cancer.
MeSH Term(s):
Grants and Funding:
Associated Publication(s):
Supplementary Data:
No Supplementary Data Available
Related Dataset(s):
No Related Dataset Data Available
The National Library of Medicine (NLM) provides information about biomedical datasets. Inclusion on an NLM Web page does not imply endorsement of, or agreement with, the contents by NLM or the National Institutes of Health. Learn more: NLM Web Policies (nih.gov)